Prognostic significance of tumor iNOS and COX-2 in stage III malignant cutaneous melanoma
| Autor: | Rolf Kiessling, Giuseppe Masucci, Bo Nilsson, Isabel Poschke, Marianne Frostvik Stolt, Suzanne Egyhazi, C. Christian Johansson, Johan Hansson, Diana Linden, Dimitrios Mougiakakos, Rainer Tuominen, Liss Garberg, Helena Harlin |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Adult
Male Proto-Oncogene Proteins B-raf Neuroblastoma RAS viral oncogene homolog Cancer Research Pathology medicine.medical_specialty Skin Neoplasms medicine.medical_treatment Immunology Nitric Oxide Synthase Type II Metastasis medicine Humans Immunology and Allergy Stage (cooking) Melanoma neoplasms Lymph node Aged Neoplasm Staging Aged 80 and over business.industry Cancer Immunotherapy Middle Aged Prognosis medicine.disease Logistic Models medicine.anatomical_structure Oncology Cyclooxygenase 2 Lymphatic Metastasis Mutation Cancer research Female Skin cancer business |
| Zdroj: | Cancer Immunology, Immunotherapy. 58:1085-1094 |
| ISSN: | 1432-0851 0340-7004 |
| Popis: | New prognostic markers are needed for malignant melanoma. Inducible nitric oxide synthase (iNOS) and cyclooxygenase type 2 (COX-2) have been described to correlate with progression of melanoma. Moreover, activating mutations in BRAF/NRAS oncogenes are often detected in melanoma. The BRAF/NRAS mutation status and expression of COX-2 and iNOS were examined to compare their prognostic value for overall survival (OS) in stage III malignant cutaneous melanoma.The expression of iNOS and COX-2 in metastatic lymph nodes from 21 rapidly progressing (OS from date of diagnosis of stage III diseaseor =14 months) and 17 slowly progressing (OSor =60 months) stage III cutaneous melanoma patients was examined by immunohistochemistry. The presence of BRAF/NRAS mutations was analyzed using direct DNA sequencing. Chi2 exact trend test and logistic regression analysis were used for statistical analysis.Both iNOS (P = 0.002) and COX-2 (P = 0.048) alone significantly predicted OS. The BRAF/NRAS mutation status did not significantly differ between patient groups, although iNOS significantly (P = 0.013) correlated with BRAF mutation frequency. Furthermore, the odds ratio (OR) with respect to OS of iNOS (OR = 10.4) was higher than that of COX-2 (OR = 5.6) and was stable in the multivariate analysis of OS together with disease stage IIIB/C, ulceration, number of metastatic lymph nodes, and Breslow tumor thickness.Our data show that iNOS is an independent and stronger prognostic factor for OS in stage III malignant cutaneous melanoma than COX-2. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink